

## COPY OF PAPERS ORIGINALLY FILED

03CO BOX SER

Dkt. 0467/57114-B/RDK/JEF

#3

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kathryn S.E. Cheah and Kenneth M.C. Cheung

Serial No. : 09/975,607

Filed : October 11, 2001

For : USE OF TRANSGENIC MOUSE CONTAINING A TYPE X

COLLAGEN MUTANT

1185 Avenue of the Americas New York, New York 10036 January 4, 2002

Assistant Commissioner for Patents Washington, D.C. 20231

Box: Sequence

Sir:

## COMMUNICATION IN RESPONSE TO NOVEMBER 14, 2001 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

This Communication is submitted in response to the November 14, 2001 Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures issued by the United States Patent and Trademark Office in connection with the above-identified application. A copy of the Notice To Comply is attached hereto as Exhibit A. The Notice provides a period of two months for filing a response. Therefore, a response to this November 14, 2001 Notice is due January 14, 2002. Accordingly, this Communication is being timely filed.

Applicant: Kathryn S.E. Cheah and Kenneth M.C. Cheung

Serial No.: 09/975,607 Filed: October 11, 2001

Page 2

The Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures indicates that the Application clearly fails to comply with the requirements of 37 C.F.R. §1.821 - 1.825. In response, applicants submit as **Exhibit B** hereto a paper copy of the Sequence Listing. In addition, applicants submit herewith a computer readable form (CRF) copy of the "Sequence Listing" as required by 37 C.F.R. §1.825(d). Further, applicants submit herewith a Statement in accordance with 37 C.F.R. §1.821(f) as **Exhibit C**, certifying that the computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information which was submitted as the "Sequence Listing" and contains no new matter.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invite the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Communication. If any other fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Applicant: Kathryn S.E. Cheah and Kenneth M.C. Cheung

Serial No.: 09/975,607
Filed: October 11, 2001

Page 3

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Robert D. Katz

Reg. No. 30,141


Respectfully submitted,


Robert D. Katz
Registration No. 30,141
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036

(212) 278-0400

/ 74101

COPY OF PAPERS ORIGINALLY FILED





ORIGINALLY FILED

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231

Www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/975,607

10/11/2001

Kathryn S.E. Cheah

57114-A

**CONFIRMATION NO. 9933** 

FORMALITIES LETTER
\*OC00000007062982\*

Robert D. Katz Cooper & Dunham, LLP 1185 Avenue of the Americas New York, NY 10036

Date Mailed: 11/14/2001

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE